BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellceutix (CTIX) Release: Coach Jim Boeheim Putting Up His Best Defense Against Michigan... and Cancer


4/5/2013 9:28:28 AM

SYRACUSE, NY--(Marketwired - April 05, 2013) - Cellceutix Corporation (OTCBB: CTIX)

Syracuse men's basketball coach Jim Boeheim is preparing his Orangemen to challenge Michigan on Saturday night in the iconic coach's bid to make it to his fourth NCAA Championship game and win a second NCAA championship title.

Away from the court, the second winningest basketball coach in NCAA Division 1 history and cancer survivor is working with a different team on a bigger battle, finding a cure for cancer. In 1996, Boeheim and his wife, Juli, became involved with Coaches vs. Cancer, a partnership program between the National Association of Basketball Coaches and the American Cancer Society devoted to eliminating cancer through research and advocacy. Since then, Boeheim has partnered in cancer efforts with other superstars like NBA All-Star and former Orangemen Carmelo Anthony and Cellceutix Corporation, a Beverly, MA-based biotechnology company with a very unique and promising cancer drug candidate.

Last May, Boeheim joined the advisory board of Cellceutix after being intrigued by its new cancer drug, called "Kevetrin," that is now being studied in human trials at Harvard's Dana-Farber Cancer Center and Beth Israel Deaconess Medical Center as a potential new treatment for various types of tumors.

Research by Cellceutix has shown Kevetrin to re-activate p53, a protein that has earned the nickname, the "Guardian Angel of the Human Genome" because of its ability to command other proteins in the body to destroy cancer cells. In nearly all cancers, p53 is muted from its normal function, but Cellceutix believes that Kevetrin has the potential of correcting the damage, returning the protein to its role as head coach of the cell cycle.

"I put 100 percent into everything that I do, whether it is preparation for a game or working to find a cure for cancer," said Boeheim. "Cellceutix's team has the same work ethic and it was a natural match. What they are working to achieve could possibly change the landscape of oncology as we know it today."

Looks like Michigan and cancer could both be in for quite a battle.

More information on Coaches vs. Cancer and the Jim and Juli Boeheim Foundation can be found by contacting:

Michael T. Bristol
Official Publicist and Marketing Manager for Jim and Juli Boeheim
mikeb@jimboeheim.com

Cellceutix is a public company traded under the ticker symbol "CTIX".
More information on Cellceutix can be found at www.cellceutix.com

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission


Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES